NCT02612285 2018-11-14Study of SNX-5422 in TP53 Null CancersEsanex Inc.Phase 2 Terminated1 enrolled 3 charts
NCT01848756 2017-02-09Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive CancersEsanex Inc.Phase 1/2 Terminated15 enrolled 10 charts